Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 20;20(1):67.
doi: 10.1186/s12968-018-0484-5.

Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification

Valentina O Puntmann  1   2 , Silvia Valbuena  3 , Rocio Hinojar  4 , Steffen E Petersen  5 , John P Greenwood  6 , Christopher M Kramer  7 , Raymond Y Kwong  8 , Gerry P McCann  9   10 , Colin Berry  11   12 , Eike Nagel  13 ; SCMR Clinical Trial Writing Group
Collaborators, Affiliations
Review

Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification

Valentina O Puntmann et al. J Cardiovasc Magn Reson. .

Abstract

Cardiovascular disease remains a leading cause of morbidity and mortality globally. Changing natural history of the disease due to improved care of acute conditions and ageing population necessitates new strategies to tackle conditions which have more chronic and indolent course. These include an increased deployment of safe screening methods, life-long surveillance, and monitoring of both disease activity and tailored-treatment, by way of increasingly personalized medical care. Cardiovascular magnetic resonance (CMR) is a non-invasive, ionising radiation-free method, which can support a significant number of clinically relevant measurements and offers new opportunities to advance the state of art of diagnosis, prognosis and treatment. The objective of the SCMR Clinical Trial Taskforce was to summarizes the evidence to emphasize where currently CMR-guided clinical care can indeed translate into meaningful use and efficient deployment of resources results in meaningful and efficient use. The objective of the present initiative was to provide an appraisal of evidence on analytical validation, including the accuracy and precision, and clinical qualification of parameters in disease context, clarifying the strengths and weaknesses of the state of art, as well as the gaps in the current evidence This paper is complementary to the existing position papers on standardized acquisition and post-processing ensuring robustness and transferability for widespread use. Themed imaging-endpoint guidance on trial design to support drug-discovery or change in clinical practice (part II), will be presented in a follow-up paper in due course. As CMR continues to undergo rapid development, regular updates of the present recommendations are foreseen.

Keywords: Biomarker; Cardiac magnetic resonance; Imaging; Position paper; SCMR.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This work represents an official publication of the SCMR and was approved by the SCMR Executive Committee. It did not undergo JCMR peer-review.

Figures

Fig. 1
Fig. 1
The illustration of reviewing steps involved in generation of this position paper. The manuscript structure, preparation and evidence appraisal procedures were based on a prior agreement within the SCMR Clinical Trial (CT) Writing Group (WG), as well as general guidance of the SCMR on Expert Consensus publications. Please see the Rationale for details
See this image and copyright information in PMC

References

    1. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91. doi: 10.1186/1532-429X-15-91. - DOI - PMC - PubMed
    1. Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson. 2013;1(15):35. doi: 10.1186/1532-429X-15-35. - DOI - PMC - PubMed
    1. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics [Internet]. 2001;69:89–95. Available from: doi 10.1067/mcp.2001.113989 - PubMed
    1. Puntmann VO, Gebker R, Duckett S, Mirelis J, Schnackenburg B, Graefe M, et al. Left ventricular chamber dimensions and wall thickness by cardiovascular magnetic resonance: comparison with transthoracic echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14:240–246. doi: 10.1093/ehjci/jes145. - DOI - PubMed
    1. Alfakih K, Plein S, Bloomer T, Jones T, Ridgway J, Sivananthan M. Comparison of right ventricular volume measurements between axial and short axis orientation using steady-state free precession magnetic resonance imaging. J Magn Reson Imaging. 2003;18(1):25–32. doi: 10.1002/jmri.10329. - DOI - PubMed

MeSH terms